Phase 3 N=151 Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Chronic GVHD
Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease
Chronic Graft Versus Host Disease
Primary: Incidence of Adverse Events — 19; 18 participants
Phase 2 N=44 Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment
Graft Versus Host Disease
Primary: Number of Participants Experiencing Treatment Success — 8 Participants
Phase 2 N=20 Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
Chronic Graft Versus Host Disease
Primary: Incidence of Adverse Events — 8; 7 participants
Phase 2 N=17 Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease
Chronic Graft Versus Host Disease
Primary: Feasibility of Enrolling Patients — 21 Participants
Phase 2 N=20 Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease
Sclerotic Graft Versus Host Disease · Imatinib Mesylate
Primary: Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months — 94; 35; 16; 21 Percent change from baseline
Phase 2 N=34 Pomalidomide for Chronic Graft-versus-Host Disease
Graft vs Host Disease · Graft-Versus-Host Disease
Primary: Overall Response at 6 Months — 0; 0; 7; 9 Participants
Phase 2 N=72 Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
Graft Versus Host Disease · Systemic Scleroderma
Primary: Significant Clinical Response — 9; 10 participants
Phase 2 N=279 Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Acute Leukemia · Chronic Myelogenous Leukemia · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants
Early Phase 1 N=60 Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
Chronic Graft Versus Host Disease
Primary: Number of Participants With an Overall Response at Week 28 — 20; 14 Participants — p=0.373
Phase 1 N=29 Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
Graft Versus Host Disease
Primary: The Maximum Tolerated Dose and Toxicity Profile of an 8 Week Course of IL-2 in Patients With cGVHD and an Inadequate Response to Steroids. — 1 million IU/m2/day
Phase 2 N=42 Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
Graft Versus Host Disease
Primary: Phase 1b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD. — 0 Participants
Phase 2 N=44 Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
Chronic Graft Versus Host Disease
Primary: Maximum Tolerated Dose of Ofatumumab — 1000 mg
Phase 2 N=22 Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
Chronic Graft Versus Host Disease
Primary: Overall Response Rate After a 15 Week Course of Bortezomib Plus Prednisone in Patients With cGVHD — 2; 14; 1; 2 participants
Phase 2 N=36 Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
Graft vs Host Disease
Primary: Clinical Activity — 4; 4 participants
Phase 2 N=46 Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Oral Chronic Graft-versus-host Disease
Primary: The Clinical Efficacy of Topical Steroid and Topical Tacrolimus Therapies for the Treatment of Oral cGHVD. — 15; 3; 11; 2 participants
Phase 3 N=236 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
Graft-versus-Host Disease · Immune System Disorders
Primary: GVHD-free Survival — 60; 69; 59; 47 participants
Phase 2 N=13 CC-4047 (Pomalidomide) for Graft vs. Host Disease
Graft vs Host Disease
Primary: Overall Response (Complete Response + Partial Response + Other) — 7; 2; 0; 0 participants
Phase 2 N=180 Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Graft vs Host Disease · Immune System Disorders
Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants
Phase 2 N=65 Rituximab for Prevention of Chronic GVHD
Hematological Malignancies
Primary: Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years — 38; 48 percentage of participants
N/A N=37 A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
Graft vs Host Disease
Primary: Number of Participants With the Ability to Successfully Taper Prednisone to a Dose Lower Dose. — 14 Participants
Phase 2 N=10 Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
Chronic GVHD
Primary: Fraction of Participants With an Overall Response Rate (Complete Response [CR] + Partial Response [PR]) Reported With an 80% Confidence Interval at 6 Months — 0; 0.1667…
Phase 2 N=54 Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease
Graft vs Host Disease
Primary: Participants That Developed Severity Score 3 or Higher Oral Chronic Graft Versus Host Disease (GVHD). — 7; 4 Participants
Phase 2 N=51 Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
Hematologic Malignancies
Primary: GVHD-free Relapse-Free Survival — 19.3 percentage of subjects
Phase 2 N=43 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Chronic GVHD Requiring Systemic Immunosuppressive Treatment — 16 percent of patients
Phase 2 N=30 Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)
GVHD, Chronic
Primary: Overall Response Rate (ORR) — 73.3 percentage of participants
Phase 2 N=10 Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease
Chronic Graft Versus Host Disease
Primary: Overall Response Rate at Week 16 (4 Weeks After the End of Treatment) — 88.9; 80.0 percentage of participants
Phase 2 N=38 Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
Graft Versus Host Disease
Primary: Response Rate — 20 percentage of participants
N/A N=6 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Changes in the Number of Recent Thymic Emigrants (RTE) Cluster of Differentiation (CD)4 T Cells in the Blood — -2; -22 cells per microliter of blood
Phase 2 N=47 Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
Graft-versus-host-disease (GVHD)
Primary: Percentage of Participants With Complete and Partial Responses in Skin and/or Joint — 49 percentage of participants